For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| CSF-1 | One drop bilaterally twice daily for at least 6 weeks CSF-1: One drop bilaterally twice daily for at least 6 weeks | 0 | None | 0 | 118 | 21 | 118 | View |
| Vehicle | One drop bilaterally twice daily for at least 6 weeks Vehicle: One drop bilaterally twice daily for at least 6 weeks | 0 | None | 0 | 60 | 15 | 60 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Conjunctival hyperaemia | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA 23.1 | View |
| Conjuctival papillae | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA 23.1 | View |
| Vision blurred | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA 23.1 | View |
| Instillation site pain | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 23.1 | View |
| COVID-19 | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDRA 23.1 | View |